TrialCard-Excellere Partnership Named Deal of the Year

Share Article

TrialCard-Excellere Partnership Named Deal of the Year

Cary, NC based healthcare solutions provider TrialCard, Incorporated announced today that its partnership with Denver, CO private equity firm Excellere Partners has been named the Deal of the Year by The Association for Corporate Growth, Raleigh Durham.

Founded in 2000, TrialCard has gained recognition as a leader in the pharmaceutical patient access space, serving many of the world’s largest manufacturers. The firm has recently expanded its suite of services to address a broader range of challenges for its clients including adherence, prescription abandonment, reimbursement support, customer experience, share of voice, case management, nursing support, patient assistance, and the need for advanced analytics to drive business decisions. The partnership with Excellere will allow TrialCard to leverage valuable relationships in the healthcare space to drive organic growth as well as explore strategic acquisition opportunities that will further solidify its position as an industry leader.

“Excellere is the ideal partner for the company’s next phase of growth because of its deep knowledge of the healthcare industry, proprietary value creation tools and processes, and proven track record of helping its partner companies achieve their goals,” commented TrialCard President and CEO Mark Bouck. “We were in search of a partner that shared our vision for growth and commitment to solving our clients’ most complex challenges. We believe that we found such a partner in Excellere.”

Brad Cornell, principal at Excellere Partners, added, “TrialCard is in a unique position to build upon its history of leadership within the patient access and medication adherence market. We are focused on enhancing the value proposition that the company provides for customers through a combination of service optimization, organic growth initiatives, and complementary acquisitions that further improve patient outcomes and drive attractive return on investments to current and prospective customers.”

“It is an honor to be recognized for this award,” stated Rob Martin, managing partner at Excellere Partners. “At Excellere, we are constantly in search for of opportunities to partner with visionary entrepreneurs and strong management teams, and we certainly have this at TrialCard. Together we look to build industry-leading medication access solutions.”

Investment banking firm Harris Williams & Co. and the Raleigh law firm Smith Anderson represented TrialCard in the process, while the Denver office of Hogan Lovells represented Excellere.

About TrialCard Incorporated
TrialCard Incorporated provides product access, medication adherence, and patient support services on behalf of pharmaceutical manufacturers. Founded in 2000, TrialCard has become the largest provider of patient access programs in the industry, processing over $1 billion in reimbursement benefits per year. TrialCard holds nine US patents related to the processing and marketing of patient access programs. The company is headquartered in Cary, North Carolina. For more information about TrialCard, please visit

About Excellere Partners
Excellere Partners is a Denver-based middle-market private equity firm that has raised $737 million of committed capital across its two funds, Excellere Capital Fund I, L.P. and Excellere Capital Fund II, L.P. The firm specializes in partnering with entrepreneurs and management teams through majority recapitalizations and management buyouts. Excellere employs a buy-and-build strategy that provides its portfolio companies with capital as well as a proprietary value creation system designed to accelerate growth while enhancing corporate infrastructure. Investments are focused on companies within the following industries: energy products and services; healthcare; industrial technology and services; business services; and specialty foods and agri-business. For more information about Excellere, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert Hastings
Follow us on
Visit website